Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of CyclASol in Dry Eye Disease (ESSENCE-2 OLE)
NCT04523142Phase 3Completed
- Sponsor
- Novaliq GmbH
- Start
- Jan 2021
- Primary completion
- Apr 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vevye in dry eye disease (DED), sponsored by Novaliq GmbH. Started Jan 2021; status: completed.
02
Drugs
vevye
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04523142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523142.